熱門資訊> 正文
葛兰素史克的Arexvy RSV疫苗在中国接受老年人监管审查
2026-02-10 21:02
- GlaxoSmithKline (GSK) said on Tuesday that China’s Center for Drug Evaluation has accepted its regulatory application for Arexvy (RSV [recombinant, adjuvanted] vaccine) for review. The vaccine is intended to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 60 and older.
- If approved, Arexvy will be the first vaccine available to this population in China to help protect against the potentially serious consequences of RSV disease.
- Respiratory Syncytial Virus vaccine (recombinant, adjuvanted) contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s (GSK) proprietary AS01E adjuvant before administration.
More on GSK
- GSK plc 2025 Q4 - Results - Earnings Call Presentation
- GSK plc (GSK) Q4 2025 Earnings Call Transcript
- GSK plc (GSK) RAPT Therapeutics, Inc. - M&A Call - Slideshow
- GSK shares uptick for seven consecutive sessions
- GSK wins EU nod to expand Nucala for COPD
推薦文章
諾和諾德稱：口服版Wegovy減肥效果優於禮來GLP‑1口服藥
美股機會日報 | 特朗普粉碎停戰幻想！恐慌指數飆升12%，納指期貨跌約2%；美油期貨暴漲超9%！油氣股飆升，美國原油基金ETF漲超9%
港股見底了嗎？北水大舉加倉逾600億港元！大行看好4月做多窗口來臨，十大金股一圖睇全
清明休市提醒 | 港股本周五休市，下周三恢復交易；美股周五休市一天
油價上漲 此前特朗普表示伊朗衝突可能在未來幾周升級
野村：特朗普講話未能發出局勢降温的明確信號
市場樂觀預期伊朗戰爭將落幕，油價跌破100美元
美股機會日報 | 緩和信號再現？特朗普考慮「帶着封鎖停戰」，三大期指齊漲！機構直言美光「跌過頭」，恐慌后或迎強勁反彈
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
